Overview OPT101 in Type 1 Diabetes Patients Status: Not yet recruiting Trial end date: 2022-10-01 Target enrollment: Participant gender: Summary Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101. Phase: Phase 1 Details Lead Sponsor: Op-T LLC